Ổ cứng Seagate và Hitachi là những loại ổ đĩa có khả năng hỏng cao nhất
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma,
a clinical-stage biopharma company targeting
debilitating central nervous system disorders
- Noema Pharma's clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs
- Jeito Capital's investment in Noema Pharma marks its second in the field of neurological disorders and represents a significant opportunity to support this promising therapeutic area with high growth potential
- Through its investment, Jeito Capital aims to promote the expansion and acceleration of Noema’s development activities and bolster value creation in France and in Europe, reinforcing its dedication to fostering the growth of biopharmaceutical champions in the region
Paris, France, March 7th 2023 - Jeito Capital ('Jeito'), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has co-led a EUR 104 million (CHF 103 million, approx. USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders. Noema Pharma has offices in Switzerland, France, and in the US.
The oversubscribed financing was co-led by Jeito and Forbion with participation from new investors such as the UPMC Enterprises joined by existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus.
Founded in 2019 in Paris, France, Noema Pharma currently has multiple active Phase 2b clinical trials in highly undertreated CNS conditions including seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has also completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended to adolescents. As part of its indication expansion strategy, the Company also anticipates initiating clinical development in Atypical Depression and Binge Eating Disorders.
Proceeds from the financing will primarily be used to advance the Company’s clinical-stage assets.
Jeito selected Noema Pharma in line with its investment strategy of supporting the development of the most promising European biopharma companies with high growth and acceleration potential. As Jeito’s second investment in a biopharma company targeting neurological diseases, Noema Pharma's maturing clinical-stage pipeline shows great promise for helping patients who currently lack effective treatments or face unmet medical needs.
In addition, Jeito will invest in Noema Pharma SAS (France), enabling it to expand its clinical trials and safety monitoring efforts in France and in Europe. This is expected to create new job opportunities and provide support for French and European suppliers in the manufacturing process. Rachel Mears, Partner at Jeito Capital, will join Noema Pharma’s Board of Directors.
Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented 'We are excited to partner with Noema Pharma in their mission to accelerate the development of innovative treatments for debilitating CNS disorders. I am particularly proud that the company born in Paris three years ago, which developed in Switzerland and the US, continues to create value in France and Europe. This reflects Jeito Capital's strong commitment to fostering the emergence of potential global biopharma leaders from Europe. As Jeito Capital's second investment in a neurology company, Noema Pharma with its clinical-stage assets and diversified pipeline has shown significant potential for the development of effective innovative therapies for the benefit of patients.'
Rachel Mears, Partner at Jeito Capital added: “One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies with high unmet medical need. The clinical work being undertaken by Noema Pharma fit these criteria exactly. The expertise, quality and dedication of the Noema team are clear to see in their development work and position the Company as an upcoming global CNS leader. We are excited to partner with Noema Pharma to accelerate its mission of developing effective solutions for patients with CNS disorders and are committed to supporting their continued growth and success.'
Luigi Costa, Chief Executive Officer of Noema Pharma said: “We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
About Jeito Capital
Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
@Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
For further information please contact:
Rafaèle Tordjman, Founder & CEO
Assia Mouhout, EA
Tel : +33 6 76 49 37 94
Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam
Tel: +44 (0) 20 3709 5700
Tel : +33 6 76 73 57 31
TIN LIÊN QUAN
AIM ImmunoTech to Participate in Solve M.E. and The
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...
Small Pharma to Host Virtual Roundtable Event with Key
LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company...
Todos Medical Enters Into Moratorium on Conversions
Moratorium Goes Into Effect After Market Close on March 13, 2023 NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, March 13, 2023 (GLOBE NEWSWIRE) --...
Mablink Bioscience to Present Promising Preclinical Data
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...
Alvotech Announces Webcast of 2022 Full Year Financial
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced...
Agenus Schedules Conference Call to Discuss the Company’s
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET...
Additional Data on Lumos OraGrowtH Trials Presented
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics...
THỦ THUẬT HAY
Cách đồng bộ hóa dữ liệu Y tế iCloud trong iOS 11
Bây giờ, Apple cho phép bạn đồng bộ dữ liệu sức khỏe của bạn ở iCloud trong iOS 11 trên iPhone và iPad.
Cách chơi game Liên quân Mobile trên máy tính
Chơi game Liên quân Mobile trên máy tính hay nói cách khác là cài đặt game Liên quân Mobile và chơi trên một trong những giả lập Android đang phổ biến trên thị trường hiện nay.
Hướng dẫn tăng tốc độ Internet trong Windows 10 version 1709
Hầu hết các bản cập nhật Windows 10 đều từ vài trăm MB đến GB, và đa số người dùng đều phàn nàn rằng kết nối internet của họ sẽ trở nên quá chậm khi Windows Update đang tải về bản cập nhật.
Cách khám phá vũ trụ và hệ mặt trời trên Google Maps
Google Maps mới cho phép người dùng thám hiểm vũ trụ, khám phá hệ mặt trời ngay trên chiếc máy tính của mình. Giờ đây việc xem Mặt trăng, Trái đất, sao Hỏa, Sao Kim, Sao Diêm Vương ngay trên Google Maps không còn là
Hướng dẫn làm USB Boot chuẩn Legacy và UEFI với DLCBoot 2017 v3.4
Dù bạn là một kỹ thuật viên máy tính hay sửa Windows dạo, hoặc chỉ đơn thuần là người thích vọc vạch thì USB cứu hộ vẫn là một thứ không thể thiếu được. Hôm nay, TECHRUM sẽ hướng dẫn các bạn cách để tạo một chiếc USB
ĐÁNH GIÁ NHANH
HP LaserJet Pro MFP M130nw: giải pháp in ấn tiết kiệm cho doanh nghiệp
Lựa chọn một chiếc máy in cho văn phòng hoặc gia đình là một vấn đề nhiều người quan tâm đến. Trong đó đối tượng khách hàng doanh nghiệp thì yếu tố giá thành và tính năng được đặt lên hàng đầu. Nếu như ‘hầu bao’ của
Điện thoại giá rẻ Samsung Galaxy A03 và những điểm cần lưu ý
Galaxy A03 – mẫu smartphone tích hợp những công nghệ tốt nhất trong phân khúc với Bộ đôi camera 48MP sắc nét, camera xóa phông nghệ thuật và bộ lọc phong phú mở rộng giới hạn sáng tạo của giới trẻ. Bên cạnh đó, dung